Role of B‐Type Natriuretic Peptide and N‐Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus

Author:

Wolsk Emil12,Claggett Brian1,Pfeffer Marc A.1,Diaz Rafael3,Dickstein Kenneth4,Gerstein Hertzel C.5,Lawson Francesca C.6,Lewis Eldrin F.1,Maggioni Aldo P.7,McMurray John J. V.8,Probstfield Jeffrey L.9,Riddle Matthew C.10,Solomon Scott D.1,Tardif Jean‐Claude11,Køber Lars2

Affiliation:

1. Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

2. Department of Cardiology, Rigshospitalet, Copenhagen, Denmark

3. Estudios Clínicos Latinoamérica, Rosario, Argentina

4. University of Bergen Stavanger University Hospital, Stavanger, Norway

5. Division of Endocrinology & Metabolism, McMaster University, Hamilton, Ontario, Canada

6. Sanofi U.S., Bridgewater, NJ

7. Research Center of the Italian Association of Hospital Cardiologists, Florence, Italy

8. British Heart Foundation Cardiovascular Research Centre, University of Glasgow, United Kingdom

9. Division of Cardiology, University of Washington Medical Center, Seattle, WA

10. Division of Endocrinology, Oregon Health and Science University, Portland, OR

11. Montreal Heart Institute, Université de Montréal, Montreal, Canada

Abstract

Background Natriuretic peptides are recognized as important predictors of cardiovascular events in patients with heart failure, but less is known about their prognostic importance in patients with acute coronary syndrome. We sought to determine whether B‐type natriuretic peptide ( BNP ) and N‐terminal prohormone B‐type natriuretic peptide ( NT ‐pro BNP ) could enhance risk prediction of a broad range of cardiovascular outcomes in patients with acute coronary syndrome and type 2 diabetes mellitus. Methods and Results Patients with a recent acute coronary syndrome and type 2 diabetes mellitus were prospectively enrolled in the ELIXA trial (n=5525, follow‐up time 26 months). Best risk models were constructed from relevant baseline variables with and without BNP / NT ‐pro BNP . C statistics, Net Reclassification Index, and Integrated Discrimination Index were analyzed to estimate the value of adding BNP or NT ‐pro BNP to best risk models. Overall, BNP and NT ‐pro BNP were the most important predictors of all outcomes examined, irrespective of history of heart failure or any prior cardiovascular disease. BNP significantly improved C statistics when added to risk models for each outcome examined, the strongest increments being in death (0.77–0.82, P <0.001), cardiovascular death (0.77–0.83, P <0.001), and heart failure (0.84–0.87, P <0.001). BNP or NT ‐pro BNP alone predicted death as well as all other variables combined (0.77 versus 0.77). Conclusions In patients with a recent acute coronary syndrome and type 2 diabetes mellitus, BNP and NT ‐pro BNP were powerful predictors of cardiovascular outcomes beyond heart failure and death, ie, were also predictive of MI and stroke. Natriuretic peptides added as much predictive information about death as all other conventional variables combined. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01147250.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3